Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg2/27 cls
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)MizuhoMario CorsoUpgradeBuy (from neutral)9%$8.86
Corso also raised his target to $14 from $6 on clinical/regulatory progress toward an anticipated 1Q15 NDA submission for Zalviso sufentanil sublingual tablet system to treat moderate to severe acute pain. He thinks it's "highly likely" FDA will approve the preprogrammed, handheld device that delivers a

Read the full 612 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers